• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2026, Vol. 28 ›› Issue (5): 863-873.DOI: 10.3969/j.issn.1671-2587.2026.05.026

Previous Articles     Next Articles

Gene Therapy for β-Thalassemia: Technological Advances, Clinical Evidence, and Translational Challenges

HU Dongjie, CHEN Liping, LIANG Bin, LI Wanwang, WU Chao, CAI Shaofeng, HONG Woxia, LI Shanglin, CHEN Qunrong   

  1. Department of Blood Transfusion, Bao'an District People's Hospital of Shenzhen, Shenzhen, Guangdong 518101
  • Received:2026-09-02 Revised:2026-09-23 Online:2026-10-20 Published:2026-11-11

Abstract: β-Thalassemia is an autosomal recessive hemoglobin disorder caused by pathogenic variants in the β-globin gene. Red blood cell transfusion with iron chelation improves patient survival but cannot correct the underlying genetic defect. Autologous hematopoietic stem and progenitor cell gene therapy offers a novel strategy to achieve sustained transfusion independence. This review summarizes the technical advances, clinical evidence, and translational challenges of gene therapy for β-thalassemia. Lentiviral gene addition delivers an exogenous β-globin expression cassette for genomic integration, whereas CRISPR nuclease editing targeting the BCL11A erythroid enhancer reactivates fetal hemoglobin. Representative products of these strategies have obtained regulatory approvals. Nuclease-mediated editing can also target the HBG1/HBG2 promoters. Base editing enables modification of fetal hemoglobin regulatory elements without generating programmed DNA double-strand breaks, and it can repair selected eligible pathogenic variants within the β-globin gene. Base editing for fetal hemoglobin regulation has entered early-stage clinical development, yet the scope of its direct gene repair is constrained by permissible base conversion types and other limitations. Prime editing can theoretically mediate all 12 classes of base substitutions and correct a subset of small insertions and deletions. Nevertheless, direct repair of the β-globin gene via base editing and prime editing is still confined to preclinical investigation. These technologies are not a simple "new-for-old replacement" of platforms. Their clinical utility is determined by editing accuracy, long-term HSPC fitness, conditioning regimen toxicity, product consistency, manufacturing costs and patient accessibility.

Key words: β-thalassemia, Gene addition, Nuclease editing, Base editing, Prime editing, Fetal hemoglobin, Hematopoietic stem and progenitor cells, Precision genome repair

CLC Number: